Dunn permanent successor to Katz at FDA neurology division

William Dunn has been promoted to director of FDA's Division of Neurology Products (DNP) from acting director. He takes over the permanent role that had not been filled since longtime division director Russell Katz announced in January 2013 that he planned to retire.

Dunn inherits a regulatory space that is challenged by the need to identify new clinical endpoints and ways to quanitify benefit and risk for diseases that are both clinically and politically urgent (see BioCentury, Feb. 11, 2013). ...